Learn more about how myelin springs back in the brain after a marathon and how these findings could help people with multiple ...

The patient support program Cycle Vita will be available for people with MS taking Bafiertam (monomethyl fumarate) starting ...

RHHBY's higher dose of multiple sclerosis drug Ocrevus did not meet its primary goal when compared to the approved 600 mg dose in relapsing multiple sclerosis patients.

Higher doses of the company’s intravenously delivered multiple sclerosis drug failed to show additional benefit in slowing ...

Tom Nolan reviews this week’s research There are so many studies published about vitamin D—about a dozen each day—it’s hard to keep up. One that stands out is a double-blind randomised controlled ...

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the Phase III MUSETTE trial comparing a high dose of OCREVUS® (ocrelizumab) intravenous (IV) infusion to the currently approved OCREVUS IV 600 ...

Uncover the future of payments as fintech transforms financial management in the UAE. Learn about the importance of financial ...

Discover how MS patients overcome challenges, raise awareness, and lead fulfilling careers in healthcare. Across the UAE, ...

(Bloomberg) -- Roche Holding AG said a high-dose version of Ocrevus, its best-selling multiple sclerosis drug, failed to outperform the original in a large study, potentially reducing the drugmaker’s ...